Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone86-21-6163-2588
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
Employees309
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
When is Zai Lab's next earnings date?
What price target have analysts set for ZLAB?
6 brokers have issued 1-year price targets for Zai Lab's shares. Their forecasts range from $34.70 to $84.00. On average, they anticipate Zai Lab's share price to reach $49.25 in the next twelve months. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Has Zai Lab been receiving favorable news coverage?
News coverage about ZLAB stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zai Lab earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Zai Lab.
Are investors shorting Zai Lab?
Zai Lab saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,510,000 shares, an increase of 10.2% from the December 15th total of 1,370,000 shares. Based on an average daily volume of 178,600 shares, the short-interest ratio is presently 8.5 days. Currently, 2.5% of the shares of the company are sold short. View Zai Lab's Current Options Chain.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Horizon Therapeutics (HZNP), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and The Medicines (MDCO).
What other stocks do shareholders of Zai Lab own?
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Founder, Chairman & CEO (Age 53)
- Mr. Tao Fu, Pres, COO & Director (Age 47)
- Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
- Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $53.10.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $3.09 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 309 workers across the globe.View Additional Information About Zai Lab.
What is Zai Lab's official website?
How can I contact Zai Lab?
Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
